Navigation Links
Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
Date:12/1/2009

Recent Reviews In Major Peer Review Journals Have Identified The PADDS As One Of The Most Promising New Developments For The Evidence-Based Assessment Of Attention And Executive Functioning Difficulties. Some Of The Most Recent Are Listed Below.

(PRWEB) December 1, 2009 -- Review written by: Leesa V. Huang Ph.D. for the Journal of Attention Disorders, Volume 13, No. 3 November 2009. A nice synopsis of this article is available on PubMed Here

Review written by: Steven Spector, Ph.D., Eric A. Youngstrom, Ph.D., Kristin D. Anderson, Psy.D. for The ADHD Report Volume 17 Number 5, October 2009

An Expert Interview with Dr. Thomas Pedigo on Evidence-Based Assessment by Laurie Barclay, MD for MedScape Today from WebMD

An in depth review from Buros Institute of Mental Measurments is scheduled to be released electronically in Test Reviews Online January of 2010 and will be included in theBuros' 18th Mental Measurments Yearbook in Spring 2010.

The Pediatric Attention Disorders Diagnostic Screener, or PADDS,
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Study suggests brain tumors need treatment with multiple targeted drugs
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Research suggests targeted treatment strategies for lupus
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
6. Gleevec, the targeted cancer pill, delivers more good news to patients
7. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
8. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
9. A major step toward a more targeted treatment for auto-immune diseases?
10. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
11. New study of targeted therapies for breast cancer -- model for global clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Targeted Testing Receives Favorable Reviews On  PADDS,  Begins  Nationwide Research Study On The Target Tests of Executive Functioning-OV
(Date:7/25/2014)... July 26, 2014 2014 ... Gel Permeation Chromatography Industry” is a professional ... and China Gel Permeation Chromatography market. The ... including Gel Permeation Chromatography definition, classification, application, ... industry overview. This research covers the international ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... dismissal and summary judgment in two DePuy Pinnacle hip ... paving the way for the claims to go before ... reports. In an opinion rendered on July 18th, U.S. ... Texas, ruled that the two Plaintiffs’ claims may proceed ...
(Date:7/25/2014)... are more easily distracted during thinking and memory tasks ... any type of memory test administered reveals a decline ... co-author Randi Martin, professor of psychology at Rice University, ... said, this study shows that "environmental interference" has a ... younger adults. The study included 60 seniors, aged ...
(Date:7/25/2014)... As reported by People Magazine in the article Mike ... Sober (7/15), one of the most popular cast stars ... the public about his personal transformation. Now, two years later ... moving on with his life was a challenge. He was ... 2012 and even spent some time in rehab. He took ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
Breaking Medicine News(10 mins):Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Distractions Seem More Troublesome With Age 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2
... , , FREMONT, Calif., Nov. 24 ... today announced the launch of the VersaWave(R) Specialty Er:YAG all-issue dental ... Greater New York Dental Meeting, November 30 - December 3, 2008 ... , "The VersaWave Specialty builds on our solid heritage ...
... results yesterday evaluating the Novo-TTF device in vitro ... the device enhanced the efficacy of standard chemotherapy ... When used in combination with standard chemotherapy, the ... intensity alternating electric fields to destroy cancer cells, ...
... and Transportation System Reduces Endoscope Cross-contamination and Protects Scopes ... New Infection Prevention Solution for Busy GI Suites , ... 24 Advanced Sterilization Products (ASP), division of Ethicon ... CLEANASCOPE System, a new infection prevention solution designed to ...
... , , MONDAY, Nov. 24 (HealthDay News) -- The interaction between ... may contribute to epileptic seizures, new research suggests. , If ... be a target for new treatments or even preventive measures ... of Nature Medicine . , "This opens a window ...
... Recognized - , , WASHINGTON, Nov. ... definitive voice for 50+ Americans and the world,s largest-circulation magazine with ... Inspire Awards . The Inspire Awards pay tribute ... innovative thinking, passion and perseverance. The 2009 honorees include Glenn ...
... developer of,LifeShirt(R), a continuous, integrated and wearable remote ... proprietary LifeShirt(R),system is being used by Concordia ... factors that may put children at risk for ... Children enrolled in ...
Cached Medicine News:Health News:HOYA ConBio(TM) Introduces VersaWave(R) Specialty Laser 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 3Health News:ASP Announces Availability of CLEANASCOPE System 2Health News:Clue to Cause of Epileptic Seizures Discovered 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 2Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 3Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 4Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 5Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 6Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 7Health News:Glenn Close, Alma Powell, and Quincy Jones to Be Honored at AARP The Magazine's 2009 Inspire Awards 8Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 2Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 3Health News:VivoMetrics' LifeShirt(R) Selected by Concordia University to Provide Patient Data for Healthy Heart Research Project 4
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... BUENA, N.J. , July 24, 2014 ... New Jersey based specialty generic pharmaceutical company, ... resignation from its Board of Directors.  Mr. Finio has ... company, and under the terms of his acceptance of ... continue in his role as Director for IGI Laboratories, ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... Results,published this week in The Lancet show that ... 6, 11,16, 18) Recombinant Vaccine) was 100 percent ... by HPV,types 16 and 18, two types strongly ... observed in women who were not,infected with HPV ...
... at 9th International Symposium on,Myelodysplastic Syndromes, TAMPA, Fla., ... a pivotal Phase II trial evaluating Revlimid in ... syndromes (MDS),were presented today by Dr. Alan List, ... Institute, at the 9th International,Symposium on MDS currently ...
Cached Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3